Get started
Author

Lawrence P. Leichman

p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.
1998 · H J Lenz, K Hayashi, et al. · PubMed · 206
A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer
1995 · Leonard B. Saltz, Cynthia G. Leichman, et al. · Cancer · 95
Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)
2010 · Philip J. Gold, Bryan Goldman, et al. · Journal of Thoracic Oncology · 61
PDF
S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma
2011 · Lawrence P. Leichman, Bryan H. Goldman, et al. · Journal of Clinical Oncology · 58
Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The gastrointestinal tumor study group experience
1990 · H. Gunter Seydel, Donald M. Stablein, et al. · Cancer · 40
Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010.
2020 · Howard Safran, Kathryn A. Winter, et al. · Journal of Clinical Oncology · 36
Impact of socioeconomic status on survival for patients with anal cancer
2018 · Daniel Lin, Heather T. Gold, et al. · Cancer · 30
PDF
Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials
2014 · Christine Min, Sripal Bangalore, et al. · Oncology · 27
High frequency of simultaneous loss of p16 and p16β gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach
1997 · Kazuhiko Hayashi, Ralf Metzger, et al. · Oncogene · 25
Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study
2024 · Chengwei Peng, Saad Saffo, et al. · Journal of the National Comprehensive Cancer Network · 14
Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center.
2015 · Danielle S Bitterman, David Grew, et al. · PubMed · 13
Phase II trial of m-AMSA in gallbladder and cholangiocarcinoma: a Southwest Oncology Group Study
1983 · Ronald M. Bukowski, Lawrence P. Leichman, et al. · European Journal of Cancer and Clinical Oncology · 13
Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205)
2019 · Michael K. Gibson, Paul Catalano, et al. · The Oncologist · 11
PDF
ECOG 2205: A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy (CRT) (IMRT permitted) with Oxaliplatin (O) and Infusional 5-Fluorouracil (5FU) Plus Cetuximab (C225) in Patients with Operable Adenocarcinoma of the Esophagus: High Risk of Post-op Adult Respiratory Distress Syndrome (ARDS)
2010 · L.R. Kleinberg, P.J. Catalano, et al. · International Journal of Radiation Oncology*Biology*Physics · 10
Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule.
1983 · R B Schilcher, J D Young, et al. · PubMed · 10
Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with irinotecan (IRI): An AGICC study.
2013 · Howard S. Hochster, Wells A. Messersmith, et al. · Journal of Clinical Oncology · 8
A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
2020 · Jennifer J. Wu, Emily Catherine Atkinson, et al. · Journal of Clinical Oncology · 6
Evaluation of treatment and outcomes for Hispanic patients with gastric cancer at Commission on Cancer‐accredited centers in the United States
2019 · Beiqun Zhao, Lawrence P. Leichman, et al. · Journal of Surgical Oncology · 6
A phase Ib study combining irinotecan with AZD1775, a selective WEE 1 kinase inhibitor, in RAS/RAF mutated metastatic colorectal cancer patients who progressed on first line therapy.
2017 · Deirdre Jill Cohen, Elda Grabocka, et al. · Journal of Clinical Oncology · 6
Food as medicine: A randomized controlled trial (RCT) of home delivered, medically tailored meals (HDMTM) on quality of life (QoL) in metastatic lung and non-colorectal GI cancer patients.
2016 · Omar Ishaq, Raymond Mailhot Vega, et al. · Journal of Clinical Oncology · 6
Phase II study of sorafenib with gemcitabine and erlotinib (GES) in first-line advanced pancreatic cancer.
2011 · D. J. Cohen, L. P. Leichman, et al. · Journal of Clinical Oncology · 6
Failure of Pretreatment With Intravenous Folic Acid to Alter the Cumulative Hematologic Toxicity of Lometrexol
1996 · F. M. MUGGIA, T. W. SYNOLD, et al. · JNCI Journal of the National Cancer Institute · 6
PDF
The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).
2013 · Howard S. Hochster, Wells A. Messersmith, et al. · Journal of Clinical Oncology · 5
Antitumor activity and immune reponse in CD40 immunotherapy with gemcitabine and nab-paclitaxel in an orthotopic pancreatic cancer mouse model.
2016 · Despina Siolas, Jane Cullis, et al. · Journal of Clinical Oncology · 4
A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.
2014 · Susan M. Domchek, Robert R. McWilliams, et al. · Journal of Clinical Oncology · 3
Works count: 41
Citation count: 713
H-index: 12
I10-index: 15
Year
Topic
Type